Related Experiment Video
Updated: Apr 9, 2026
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
XI-006 induces potent p53-independent apoptosis in Ewing sarcoma
Kathleen I Pishas1,2, Alaknanda Adwal2, Susan J Neuhaus3
1Sarcoma Research Group, Discipline of Medicine, University of Adelaide, Adelaide, Australia.
Abstract:
There is an imperious need for the development of novel therapeutics for the treatment of Ewing sarcoma, the second most prevalent solid bone tumour observed in children and young adolescents. Recently, a 4-nitrobenzofuroxan derivative, XI-006 (NSC207895) was shown to diminish MDM4 promoter activity in breast cancer cell lines. As amplification of MDM4 is frequently observed in sarcomas, this study examined the therapeutic potential of XI-006 for the treatment of Ewing and osteosarcoma. XI-006 treatment of Ewing and osteosarcoma cell lines (n = 11) resulted in rapid and potent apoptosis at low micro-molar concentrations specifically in Ewing sarcoma cell lines (48 hr IC50 0.099-1.61 μM). Unexpectedly, apoptotic response was not dependent on MDM4 mRNA/protein levels or TP53 status. Alkaline/neutral comet and γH2AX immunofluorescence assays revealed that the cytotoxic effects of XI-006 could not be attributed to the induction of DNA damage. RNA expression analysis revealed that the mechanism of action of XI-006 could be accredited to the inhibition of cell division and cycle regulators such as KIF20A and GPSM2. Finally, potent synergy between XI-006 and olaparib (PARP inhibitor) were observed due to the down-regulation of Mre11. Our findings suggest that XI-006 represents a novel therapeutic intervention for the treatment of Ewing sarcoma.
Insights
A novel compound, XI-006, shows potent therapeutic potential against Ewing sarcoma, a rare childhood bone cancer. This drug effectively induces cancer cell death without causing DNA damage, offering a promising new treatment avenue.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Ewing sarcoma is a prevalent pediatric bone cancer lacking effective treatments.
- MDM4 amplification is common in sarcomas, suggesting it as a therapeutic target.
- XI-006, a 4-nitrobenzofuroxan derivative, previously reduced MDM4 promoter activity in breast cancer.
Purpose of the Study:
- To investigate the therapeutic potential of XI-006 in Ewing sarcoma and osteosarcoma.
- To elucidate the mechanism of action of XI-006 in sarcoma cell lines.
Main Methods:
- Treatment of 11 Ewing and osteosarcoma cell lines with XI-006.
- Apoptosis assays, MDM4 mRNA/protein level analysis, TP53 status assessment.
- Alkaline/neutral comet assays and γH2AX immunofluorescence for DNA damage.
- RNA expression analysis to identify molecular targets.
- Synergy studies with olaparib (PARP inhibitor).
Main Results:
- XI-006 induced rapid apoptosis in Ewing sarcoma cell lines at low micromolar concentrations (IC50 0.099-1.61 μM).
- Apoptosis was independent of MDM4 levels and TP53 status.
- XI-006 did not induce significant DNA damage.
- Mechanism involves inhibition of cell division regulators KIF20A and GPSM2.
- Synergistic effect observed with olaparib due to Mre11 downregulation.
Conclusions:
- XI-006 demonstrates significant therapeutic potential as a novel agent for Ewing sarcoma.
- The drug's efficacy is linked to cell cycle regulation, not DNA damage induction.
- Combination therapy with PARP inhibitors may enhance XI-006 effectiveness.
More Related Videos
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
13:54Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death
Published on: October 21, 2012
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:23Abnormal Proliferation